Deciphera Pharmaceuticals. has filed a patent for a method of inhibiting TIE2 kinase to treat the growth of venous malformations. The method involves administering a compound of Formula I to patients with TIE2 kinase-mediated vascular anomalies. GlobalData’s report on Deciphera Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Deciphera Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Deciphera Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Deciphera Pharmaceuticals's grant share as of September 2023 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Inhibiting tie2 kinase for treating vascular anomalies

Source: United States Patent and Trademark Office (USPTO). Credit: Deciphera Pharmaceuticals Inc

A recently filed patent (Publication Number: US20230277522A9) describes a method for treating TIE2 kinase-mediated vascular anomalies or TIE2 kinase mutant-mediated vascular anomalies in patients. The method involves administering a compound of Formula I to the patient in a therapeutically effective amount. The pharmaceutically acceptable salt tosylate is mentioned as an option for the compound.

The patent claims that the vascular anomalies being treated are slow-flow malformations, specifically capillary malformations, lymphatic malformations, or venous malformations. Venous malformations are highlighted as a specific type of slow-flow malformation.

The method of treatment can involve administering the compound of Formula I to the patient once daily, intermittently, every other day, every third day, every other week, twice daily, once weekly, or twice weekly. The patent also mentions specific dosage ranges for the compound, ranging from about 57 mg to about 1200 mg daily. However, a specific dosage of about 100 mg daily is mentioned as a preferred option. Other dosage options mentioned include about 150 mg, 200 mg, or 300 mg once or twice daily.

Additionally, the patent claims a method for treating vascular anomalies in general, not limited to TIE2 kinase-mediated anomalies. This method also involves administering the compound of Formula I to the patient in a therapeutically effective amount.

The patent further suggests combining the treatment with a second therapeutic agent. Specifically, the patent mentions VEGF inhibitors, Akt inhibitors, mTOR inhibitors, and PI3K inhibitors as potential options for the second therapeutic agent. Various specific inhibitors are listed for each category, including pazopanib, bevacizumab, cabozantinib, sunitinib, sorafenib, axitinib, regorafenib, ponatinib, and many others.

Lastly, the patent claims a method specifically for treating venous malformations. This method involves administering about 100 to about 200 mg of the compound of Formula I to the patient once or twice daily.

Overall, the patent describes a method for treating TIE2 kinase-mediated vascular anomalies or TIE2 kinase mutant-mediated vascular anomalies using a compound of Formula I. The patent also suggests combining this treatment with a second therapeutic agent, such as VEGF inhibitors, Akt inhibitors, mTOR inhibitors, or PI3K inhibitors. The specific dosages and administration schedules are provided, along with a preferred dosage of about 100 mg daily. Additionally, a specific method for treating venous malformations is claimed, involving a dosage range of about 100 to about 200 mg once or twice daily.

To know more about GlobalData’s detailed insights on Deciphera Pharmaceuticals, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies